Madeleine Anderson

2 weeks ago | nursinginpractice.com | Madeleine Anderson

The Royal College of Nursing’s (RCN) professional lead for primary care nursing sat down with Nursing in Practice to discuss how the college is working to improve the ‘precarious position’ of practice nursing by encouraging leadership opportunities and challenging pay disparity between NHS and general practice nurses (GPNs).

2 weeks ago | nursinginpractice.com | Madeleine Anderson

There is still a ‘long way to go’ on improving the Nursing and Midwifery Council’s (NMC) fitness to practise (FtP) caseload and process, a council meeting has heard. There has been a gradual decline in the nursing regulator’s FtP caseload since the start of this year, but the caseload number is still above what it was during the same period in 2024.

2 weeks ago | nursinginpractice.com | Madeleine Anderson

Frances Baverstock is the primary care nurse lead at Betsi Cadwaldr Health Board in Wales and a member of the Royal College of Nursing’s (RCN) General Practice Nurse (GPN) Forum. She shares her views on work needed to bring more student and newly qualified nurses into general practice, following an emergency debate on the shortage of roles for newly registered nurses at RCN Congress last week.

2 weeks ago | nursinginpractice.com | Madeleine Anderson

Nurses must do more to champion men’s mental health and flag male patients to domestic abuse and suicide support services, those among the profession have urged. Nursing staff from across primary and secondary care settings shared their personal and professional experiences of male mental and physical health support at a debate at the Royal College of Nursing (RCN) Congress in Liverpool last week.

2 weeks ago | nursinginpractice.com | Madeleine Anderson

NICE has updated its guidance to no longer recommend nirmatrelvir plus ritonavir for some risk groups including the over-70s. The antiviral, also known as Paxlovid, is no longer cost effective in the over-70s as well as people with diabetes, obesity and heart failure, the new recommendations said. It follows a partial review in March 2024 that extended access to the drug to a broader population than those who had already been eligible because they were most at risk from severe disease.